Omeros
About OmerosPipelineInvestorsNews


2013 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
12/18/13FDA Grants Orphan Drug Designation to Omeros' OMS721 for Complement-Mediated Thrombotic Microangiopathies
-- Phase 2 Program Expected to Begin Next Quarter -- SEATTLE, Dec. 18, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for prevention of complement-mediated thrombotic microangiopathi... 
 Printer Friendly Version
12/05/13Omeros to Present at Oppenheimer 24th Annual Healthcare Conference
SEATTLE, Dec. 5, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference in New York City next week.  The presentation is scheduled for Wednesday, December 11, 201... 
 Printer Friendly Version
11/20/13Omeros Announces FDA Acceptance of Omidria™ as Proprietary Name for OMS302
-- European Medicines Agency Review of Proposed Names to be Completed Soon -- SEATTLE, Nov. 20, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that the U.S. Food and Drug Administration (FDA) accepted the proposed brand name Omidria™ for OMS302, the Company's proprietary product in development for use in intraoperative lens replacement (ILR) surgery. FDA's acceptance of the proprietary brand name is subject to the Agency's final determination prior to any approval of th... 
 Printer Friendly Version
11/19/13Omeros Reports Phase 3 OMS302 Clinical Data Presented at the Annual American Academy of Ophthalmology Meeting
-- In These Clinical Trials, OMS302 Reduced Incidence of Miosis -- SEATTLE, Nov. 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement (ILR). OMS302 is the company's proprietary Pharmacosurgery® product being developed for all ILR, including cataract surgery and refractive lens exchange. The analyses were presented ... 
 Printer Friendly Version
11/12/13Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
-- OMS302 also to be Featured in "Cutting Edge" Symposium -- SEATTLE, Nov. 12, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it will present data from its Phase 3 clinical program for OMS302 at the American Academy of Ophthalmology (AAO) Annual Meeting, which will take place from November 16 through November 19 in New Orleans, Louisiana. The presentation, "Two Phase 3 Trials of OMS302 in Irrigation Solution for Maintenance of Mydriasis in Intraocular Lens Replace... 
 Printer Friendly Version
11/07/13Omeros Announces Positive Data in Phase 1 Clinical Trial with OMS721
-- Phase 2 Program Expected to Begin Enrollment Next Quarter -- SEATTLE, Nov. 7, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive clinical data in a Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), an important regulator of the lectin pathway of the immune system. Subcutaneous administration of OMS721 achieved a high degree of lectin pathway inhibition. The drug ... 
 Printer Friendly Version
11/07/13Omeros Corporation Reports Third Quarter 2013 Financial Results
-- Obtains Additional $17.4 Million in Cash in 4Q 2013 -- SEATTLE, Wash., Nov. 7, 2013 /PRNewswire/ -- Received $17.4 million in cash in October 2013 Total operating expenses in 3Q 2013 were $13.6 million including $3.2 million in non-cash expenses compared to $13.3 million including non-cash expenses of $2.1 million in 2Q 2013 U.S. and European regulators accepted Omeros' OMS302 marketing applications for review OMS824 and OMS721 Phase 1 clinical programs generated positive data ... 
 Printer Friendly Version
11/05/13Omeros Announces Positive OMS721 Data in Model of Age-Related Macular Degeneration
-- Ongoing Clinical Program for OMS721 Continues to Advance -- SEATTLE, Nov. 5, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in a well-established animal model of neovascular age-related macular degeneration (AMD), which is characterized by abnormal growth of new blood vessels behind the retina of the eye and is a leading caus... 
 Printer Friendly Version
10/17/13Omeros Reports Additional Positive Clinical Data for its Drug Candidate to Treat Cognitive Disorders
-- PDE10 Target Engagement Continues to Increase with Well-Tolerated Doses - SEATTLE, Oct. 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This latest clinical trial evaluated the extent to which OMS824, at a dose higher than previously reported, binds to PDE10, an enzyme expressed in the region of the brain that has been linked ... 
 Printer Friendly Version
10/17/13Omeros Corporation Files Universal Shelf Registration Statement to Replace Expiring Universal Shelf Registration Statement
SEATTLE, Oct. 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed a replacement universal shelf registration statement (the "2013 Registration Statement") with the Securities and Exchange Commission (the "SEC"). The 2013 Registration Statement was filed as routine course of business due to the impending expiration of the company's existing universal shelf registration statement (the "2010 Registration Statement") that, under SEC rules, would have expired ... 
 Printer Friendly Version
10/15/13FDA Agrees with Omeros' Pediatric Study Plan for OMS302
-- Completion of Pediatric Study Can Lead to Additional Marketing Exclusivity - SEATTLE, Oct. 15, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) confirmed its agreement with the Pediatric Study Plan (PSP) proposed by Omeros to study the use of OMS302 in pediatric patients undergoing primary cataract extraction. The FDA also issued a Written Request consistent with the PSP, which means that successful completion of the PS... 
 Printer Friendly Version
10/08/13Omeros Hires Michael K. Inouye to Lead Commercial Operations
SEATTLE, Oct. 8, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company with marketing applications for its lead product OMS302 for use during lens replacement surgery currently under review in both the US and Europe, today announced the appointment of Michael K. Inouye as vice president, commercial operations. Mr. Inouye has over 20 years of management experience in the pharmaceutical industry.  His experience includes positions as senior vice pre... 
 Printer Friendly Version
10/03/13Omeros Settles Insurance Litigation
-- Omeros to Receive $12.5 Million -- SEATTLE, Oct. 3, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced today that it entered into a settlement agreement with its insurer, Carolina Casualty Insurance Company (CCIC), related to CCIC's defense of, and coverage obligations owed to, Omeros and its chief executive officer and chairman, Gregory A. Demopulos, M.D., in previously settled litigation with Omeros' former chief financial officer. The settlement includes a release of each ... 
 Printer Friendly Version
10/03/13Omeros Unlocks Six Additional Class A Orphan GPCRs and Identifies Small Molecules Targeting Two Commercially Validated Class B GPCRs
-- Brings Omeros' Total to 52 Class A Orphans and Opens Way to New Oral Drugs to Treat Diabetes and Osteoporosis -- SEATTLE, Oct. 3, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of six additional orphan G protein-coupled receptors (GPCRs)  that have been linked to a wide range of diseases in the areas of neurologic disorders, cardiovascular disease and oncology. Identification of compounds that fun... 
 Printer Friendly Version
10/02/13US and European Regulators Accept for Review OMS302 Marketing Applications
-- OMS302 Remains on Track for Planned 2014 Commercial Launch -- SEATTLE, Oct. 2, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced today that the New Drug Application (NDA) for its ophthalmology product, OMS302, has been confirmed for filing by the U.S. Food and Drug Administration (FDA), which means that the application, submitted in July of this year, is sufficiently complete to permit a substantive review. The company also announced that its Marketing Authorization Applicat... 
 Printer Friendly Version
09/30/13FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
-- Phase 2 Clinical Trial in Huntington's Disease Slated to Begin This Year -- SEATTLE, Sept. 30, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced that OMS824, its phosphodiesterase 10 (PDE10) inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntingto... 
 Printer Friendly Version
09/20/13Omeros Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference
SEATTLE, Sept. 20, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the NewsMakers in the Biotech Industry 2013 Conference in New York City next week.  The presentation is scheduled for Friday, September 27... 
 Printer Friendly Version
09/19/13Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
-- PDE10 Inhibitor Administered to Patients with Schizophrenia -- SEATTLE, Sept. 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ:OMER) today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia. The... 
 Printer Friendly Version
09/12/13Omeros Reports Additional Positive Results from OMS824 Program
-- Phase 1 Trial Data Predict Substantially Greater Target Engagement with Better Tolerability Than Seen with Other PDE10 Inhibitors -- SEATTLE, Sept. 12, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the Company's Phase 1 clinical trial evaluating the pharmacokinetics of OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program, further supporting that OMS824 can achieve superior target engagement with lesser side effect... 
 Printer Friendly Version
09/10/13Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
- European Market Launch Planned for Second Half of 2014 - SEATTLE, Sept. 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market OMS302 for use in patients undergoing intraocular lens replacement (ILR) surgery in the European Union (EU). Added to standard irrigation solution used during ILR, OMS302 is Omeros' proprietary PharmacoSurgery® ... 
 Printer Friendly Version
09/09/13Omeros to Present at the Stifel Healthcare Conference 2013
SEATTLE, Sept. 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Stifel Healthcare Conference 2013 in Boston, Massachusetts this week. The presentation is scheduled for 2:40 p.m. Eastern time on Thurs... 
 Printer Friendly Version
08/13/13Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
SEATTLE, Aug. 13, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, has announced that Michael A. Jacobsen is joining the company as vice president, finance and chief accounting officer. "Mike's experience leading finance teams responsible for the commercial launch of biopharmaceutical products in... 
 Printer Friendly Version
08/09/13Omeros Corporation Reports Second Quarter 2013 Financial Results
SEATTLE, Aug. 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013. Financial Results Total operating expenses for the quarter ended June 30, 2013 were $13.3 million and included non-cash expenses of $2.1 million related to re... 
 Printer Friendly Version
08/08/13Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
SEATTLE, Aug. 8, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it will present at the Wedbush 2013 Life Sciences Management Access Conference next week.  Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at 9:45 a.m. Eastern Time on Wednesday, August 14, 2... 
 Printer Friendly Version
08/01/13Omeros Submits New Drug Application to U.S. FDA for OMS302
- Submission of European Marketing Authorization Application Planned for this Quarter - SEATTLE, Aug. 1, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced that the company recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for approval of OMS302 for use in patients undergoing intraocular lens replacement (ILR) surgery. Added to standard irrigation solution used during ILR, OMS302 is Omeros' proprietary PharmacoSurgery™ product that, across ... 
 Printer Friendly Version
07/02/13European Medicines Agency Approves Positive Opinion on Omeros' Pediatric Investigation Plan for OMS302
-- Submission of Marketing Authorization Application Remains on Track for Mid-Year-- SEATTLE, July 2, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the European Medicines Agency (EMA) approved a positive opinion issued by the European Pediatrics Committee (PDCO) agreeing to the Company's Pediatric Investigation Plan (PIP) for OMS302. EMA's approval of PDCO's positive opinion is a prerequisite for submission of the OMS302 Marketing Authorization Application (MAA) ... 
 Printer Friendly Version
06/13/13Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program
-- Enrollment Expected to Begin Next Month -- SEATTLE, June 13, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program. The first clinical trial with OMS721 will be conducted in Europe and will evaluate the safet... 
 Printer Friendly Version
05/31/13Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
-- OMS824 Achieves High Target Occupancy without Causing Movement Disorders Seen with Other PDE10 Inhibitors -- SEATTLE, May 31, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program. This study measured the extent to which OMS824 binds to PDE10 in the basal ganglia, a region of the brain that has been linked to a wide range of diseases that af... 
 Printer Friendly Version
05/28/13Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
-- Phase 1 Clinical Trial Expected to Begin Early Next Quarter -- SEATTLE, Wash., May 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed a Clinical Trial Application (CTA) with European regulators to initiate clinical trials evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program. The lead indication for OMS721 will be atypical hemolytic uremic syndrome (aHUS), a rare... 
 Printer Friendly Version
05/23/13Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
-- Clinical Trial in Patients with Huntington's Disease Slated to Begin Next Quarter -- SEATTLE, May 23, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an enzyme expressed in areas of the brain linked to a wide range of diseases that affect ... 
 Printer Friendly Version
05/22/13Omeros to Present at Two Upcoming Conferences
SEATTLE, May 22, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the following two conferences: 38th Annual Deutsche Bank dbAccess Health Care Conference May 29, 2013 2:10 p.m. EDT Boston, MA Jeff... 
 Printer Friendly Version
05/14/13Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
SEATTLE, May 14, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that it closed the registered direct offering of 3,903,004 shares of its common stock that was announced on May 9, 2013.  The shares were sold at a price of $4.14 per share, which represented a two percent premium over the closing price on May 8, 2013.  The shares were sold directly to affiliates of RA Capital Management and other investors without an underwriter or placement agent. Omeros received net proceed... 
 Printer Friendly Version
05/10/13Omeros Corporation Reports First Quarter 2013 Financial Results
SEATTLE, May 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the first quarter of 2013. Financial Results Total operating expenses for the quarter ended March 31, 2013 were $11.1 million compared to $9.6 million for the same period in 2012. The ... 
 Printer Friendly Version
05/09/13Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
SEATTLE, May 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium over the closing price on May 8, 2013, for gross proceeds of $16.2 million. The shares were offered and are expected to be sold to RA Capital Management and other investors in a registered direct offering conducted without an underwriter or placement agent. The net proceeds from the offering, af... 
 Printer Friendly Version
05/01/13Omeros Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease
-- Phase 2 Clinical Trial Slated to Begin This Year -- SEATTLE, May 1, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has requested Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the development of OMS824 for the treatment of Huntington's disease. OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease... 
 Printer Friendly Version
04/30/13Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
-- Centralized Procedure Used for Products that Represent Therapeutic Innovation -- SEATTLE, April 30, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the European Medicines Agency (EMA) has confirmed that the Company's planned Marketing Authorization Application (MAA) for its ophthalmology product OMS302 can be submitted and reviewed under the EMA's centralized procedure. OMS302, which contains mydriatic (pupil-dilating) and anti-inflammatory agents, is the Compan... 
 Printer Friendly Version
04/25/13Omeros Reports OMS302 Clinical Data Presented at the Annual ASCRS and ASOA Symposium and Congress
-- Data Show that OMS302 Maintains Pupil Size During Lens Replacement Surgery by Not Only Promoting Mydriasis but also by Preventing Miosis -- SEATTLE, April 25, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 2 and Phase 3 clinical data showing the favorable impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement (ILR). OMS302, which contains a mydriatic (pupil-dilating) agent and an anti-inflammato... 
 Printer Friendly Version
04/24/13Omeros to Present at the 12th Annual Needham Healthcare Conference
SEATTLE, April 24, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it will present at the 12th Annual Needham Healthcare Conference next week.  Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at 8:40 a.m. Eastern Time on Wednesday, May 1, 2013. The pres... 
 Printer Friendly Version
04/19/13Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
SEATTLE, April 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it will present additional data from recent clinical trials evaluating its ophthalmology product, OMS302, at the Annual American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Symposium and Congress taking place in San Francisco April 19-23. The podium presentation, "Effect of an Anti-inflammatory-Mydriatic Agent on the Incidence of Intraoperative Miosis Du... 
 Printer Friendly Version
04/17/13Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
-- Orphan Drug Designation Could Provide Financial Incentives and Faster Regulatory Review -- SEATTLE, April 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP‑2) program, for use in the treatment of atypical hemolytic uremic syndrome (aHUS). As Om... 
 Printer Friendly Version
04/10/13Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
- Adds to Earlier Data Demonstrating Potential to Restore Myelin in MS Patients - SEATTLE, April 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPC... 
 Printer Friendly Version
04/02/13Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
-- Support Advancing Initial Clinical Indication of Atypical Hemolytic Uremic Syndrome -- SEATTLE, April 2, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in a well-established animal model of thrombotic microangiopathy (TMA), a disorder that occurs in the microcirculation (e.g., venules and capillaries) of the body's organs, mo... 
 Printer Friendly Version
03/29/13Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
SEATTLE, March 29, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it has been chosen to present at the 2013 Future Leaders in the Biotech Industry Conference.  Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at 9:30 a.m. Eastern Time on Friday, April 5, 2... 
 Printer Friendly Version
03/28/13Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
-- European Clinical Trial Application Submission Expected in the Second Quarter of 2013 -- SEATTLE, March 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program. In non-human primates and rodents, there were no drug-related findings in the toxicology assessments, including gross pathology, histopathology (still o... 
 Printer Friendly Version
03/26/13Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
-- Data Predict OMS824 has Greater Brain Activity without Movement Side-Effects Seen with other PDE10 Inhibitors -- SEATTLE, March 26, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the multiple-ascending-dose (MAD) portion of the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. With these data and the previously announced successful single-ascending-dose portion of this clinical t... 
 Printer Friendly Version
03/19/13Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
-- Clinical Entry Planned for Second Half of 2013 -- SEATTLE, March 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has elucidated the mechanism of action of its phosphodiesterase 7 (PDE7) inhibitors in the neural network shown to be responsible for addiction in humans. Omeros believes that it is the first to discover the link between PDE7 and any addiction or compulsive disorder, and the Company is establishing a broad intellectual property position around ... 
 Printer Friendly Version
03/18/13Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
SEATTLE, March 18, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2012. Financial Results Total operating expenses for the three months ended December 31, 2012 were $9.1 million, compared to $11.0 million ... 
 Printer Friendly Version
03/01/13Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
SEATTLE, March 1, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Cowen and Company 33rd Annual Health Care Conference next week.  The presentation is scheduled for 11:20 a.m. Eastern Time... 
 Printer Friendly Version
02/07/13Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
-- IND/CTA Submission Expected in the Second Quarter of 2013 -- SEATTLE, Feb. 7, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin associated serine protease-2 (MASP-2) program. Based on the data from these nonhuman primate studies, OMS721 is expected to be delivered subcutaneously to patients at a convenient dosing schedule of weekly, bi-monthly or even les... 
 Printer Friendly Version
01/22/13Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
-- Market Launch Expected First Half of 2014 -- SEATTLE, Jan. 22, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery™ product desi... 
 Printer Friendly Version
01/16/13Omeros Identifies Small Molecules for Class B GPCR
- Expands "Unlocking" Capability Beyond Class A Orphan GPCRs - SEATTLE, Jan. 16, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its proprietary Cellular Redistribution Assay (CRA) technology, which to date has successfully "unlocked" 46 of the 80 total Class A orphan G Protein-Coupled Receptors (GPCRs) for drug development, has identified small molecules that interact with a Class B GPCR. Like the Class A GPCRs, Class B receptors are important players in a broad r... 
 Printer Friendly Version